Latest Conference Articles

February 22nd 2019, 11:31pm

Transplantation and Cellular Therapy Meetings

Shaji Kumar, MD, of Mayo Clinic, advises physicians on the use of autologous stem cell transplant in patients with newly diagnosed multiple myeloma.

February 22nd 2019, 11:14pm

Transplantation and Cellular Therapy Meetings

Frederick L. Locke, MD, discusses the optimal management of chimeric antigen receptor T-cell therapy-related adverse events.

February 22nd 2019, 8:44pm

Transplantation and Cellular Therapy Meetings

Patients with relapsed/refractory chronic lymphocytic leukemia had an improved response rate with chimeric antigen receptor T-cell therapy if they also received ibrutinib.

February 22nd 2019, 2:35am

Transplantation and Cellular Therapy Meetings

Adults with acute lymphoblastic leukemia had worse outcomes, including lower survival, after myeloablative allogeneic transplantation if they remained positive for minimal residual disease at the time of transplant.

February 21st 2019, 7:26pm

Transplantation and Cellular Therapy Meetings

Gareth Morgan, MD, discusses the TOURMALINE-MM3 findings in multiple myeloma and other clinical trials that are impacting the landscape for this patient population.

February 18th 2019, 10:25pm

Genitourinary Cancers Symposium (ASCO GU)

Arlene O. Siefker-Radtke, MD, discusses the promising preliminary data with bempegaldesleukin plus nivolumab in patients with metastatic urothelial carcinoma and the next steps for this combination.

February 18th 2019, 1:13am

Genitourinary Cancers Symposium (ASCO GU)

Single-agent pembrolizumab (Keytruda) showed encouraging antitumor activity as first-line treatment in patients with non-clear cell renal cell carcinoma, especially in those with papillary or unclassified histology.

February 18th 2019, 12:45am

Genitourinary Cancers Symposium (ASCO GU)

Evan Y. Yu, MD, highlights 2 key studies with PARP inhibitors in metastatic castration-resistant prostate cancer and discussed challenges that need to be addressed in this space in order to further progress.

February 17th 2019, 9:23pm

Genitourinary Cancers Symposium (ASCO GU)

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of bempegaldesleukin plus nivolumab in the treatment of patients with metastatic urothelial carcinoma.

February 17th 2019, 9:20pm

Genitourinary Cancers Symposium (ASCO GU)

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses durvalumab in combination with a MET inhibitor in the treatment of patients with papillary renal cancer.

February 17th 2019, 7:53pm

Genitourinary Cancers Symposium (ASCO GU)

The overall response rate achieved with with the combination of savolitinib and durvalumabin in patients with metastatic papillary renal cell carcinoma in the phase II CALYPSO study did not meet the prespecified criterion for further investigation of the regimen.

February 17th 2019, 1:44am

Genitourinary Cancers Symposium (ASCO GU)

The combination of pembrolizumab (Keytruda) and cabozantinib (Cabometyx) has antitumor activity in patients with previously treated metastatic renal cell carcinoma and is tolerated at their separate approved doses for this indication.

February 16th 2019, 11:26pm

Genitourinary Cancers Symposium (ASCO GU)

Sacituzumab govitecan exhibited significant clinical activity in an open-label, single-arm phase I/II basket study of patients with heavily pretreated, relapsed/refractory metastatic urothelial cancer.

February 16th 2019, 10:53pm

Genitourinary Cancers Symposium (ASCO GU)

Arpita Desai, MD, medical oncologist, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the rationale for testing MRI functional imaging for bone metastases in men with castration-resistant prostate cancer.

February 16th 2019, 10:50pm

Genitourinary Cancers Symposium (ASCO GU)

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses avelumab/axitinib data in renal cell carcinoma.

February 16th 2019, 1:50am

Genitourinary Cancers Symposium (ASCO GU)

In a real-world setting, patients with metastatic castration-resistant prostate cancer who received radium-223 dichloride with abiraterone acetate in a layered fashion experienced a lower rate of symptomatic skeletal events compared with those who received the treatments concurrently.

February 16th 2019, 12:27am

Genitourinary Cancers Symposium (ASCO GU)

The addition of enzalutamide (Xtandi) to androgen deprivation therapy significantly prolonged radiographic progression-free survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.

February 16th 2019, 12:26am

Genitourinary Cancers Symposium (ASCO GU)

Darolutamide added to androgen deprivation therapy significantly improved metastasis-free survival compared with placebo plus ADT in patients with nonmetastatic castration-resistant prostate cancer enrolled in the phase III ARAMIS trial.

February 15th 2019, 9:05pm

Genitourinary Cancers Symposium (ASCO GU)

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the rationale for the KEYNOTE-057 study in patients with non–muscle invasive bladder cancer.

February 15th 2019, 9:01pm

Genitourinary Cancers Symposium (ASCO GU)

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses sacituzumab govitecan in the treatment of patients with urothelial carcinoma.